Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

BACKGROUND: Uterine and ovarian carcinosarcomas (CS) are rare but highly aggressive gynecologic tumors which carry an extremely poor prognosis. We evaluated the expression levels of EpCAM and the in vitro activity of solitomab, a bispecific single-chain antibody construct which targets epithelial-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrari, Francesca, Bellone, Stefania, Black, Jonathan, Schwab, Carlton L., Lopez, Salvatore, Cocco, Emiliano, Bonazzoli, Elena, Predolini, Federica, Menderes, Gulden, Litkouhi, Babak, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609066/
https://www.ncbi.nlm.nih.gov/pubmed/26474755
http://dx.doi.org/10.1186/s13046-015-0241-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609066/
https://www.ncbi.nlm.nih.gov/pubmed/26474755
http://dx.doi.org/10.1186/s13046-015-0241-7

Ejemplares similares